EGF-ERBB signalling: Towards the systems level

Nature Reviews Molecular Cell Biology

Volumn 7, Issue 7, 2006, Pages 505-516

  Citri, Ami ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; LIGAND; PELITINIB; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; TRASTUZUMAB;

CANCER; CELL COMPARTMENTALIZATION; CELL MATURATION; CELL NUCLEUS; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME STRUCTURE; EPITHELIUM; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ENDOCYTOSIS; EPIDERMAL GROWTH FACTOR; FEEDBACK, BIOCHEMICAL; HUMANS; LIGANDS; MODELS, MOLECULAR; ONCOGENE PROTEINS V-ERBB; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33745828702     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm1962     Document Type: Review

References (142)

1. Klapper, L. N. et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl Acad. Sci. USA 96, 4995-5000 (1999).
2. Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A. & Carraway, K. L. 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl Acad. Sci. USA 91, 8132-8136 (1994).
3. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
4. Stelling, J., Sauer, U., Szallasi, Z., Doyle, F. J. 3rd & Doyle, J. Robustness of cellular functions. Cell 118, 675-685 (2004).
5. Kitano, H. Biological robustness. Nature Rev. Genet. 5, 826-837 (2004). An introductory text to systems biology that describes the principles of robustness in biological systems.
6. Schulze, W. X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1, 42-54 (2005).
7. Levkowitz, G. et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4, 1029-1040 (1999). Identified c-Cbl as the phospho-activated ubiquitin-ligase that mediates EGF-receptor degradation.
8. Miettinen, P. J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337-341 (1995).
9. Threadgill, D. W. et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230-234 (1995).
10. Sibilia, M. & Wagner, E. F. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269, 234-238 (1995).
11. Sibilia, M., Steinbach, J. P., Stingl, L., Aguzzi, A. & Wagner, E. F. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J. 17, 719-731 (1998). References 8-11 describe the phenotypes of Egfr knockouts that show variable defects depending on genetic background.
12. Luetteke, N. C. et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126, 2739-2750 (1999).
13. Mann, G. et al. Mice with null mutations of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73, 249-261 (1993).
14. Troyer, K. L. et al. Growth retardation, duodenal lesions, and aberrant ileum architecture in triple null mice lacking EGF, amphiregulin, and TGF-α. Gastroenterology 121, 68-78 (2001).
15. Luetteke, N. C. et al. TGFα deficiency results in hair follicles and eye abnormalities in targeted and waved-1 mice. Cell 73, 263-278 (1993). References 12-15 describe the phenotypes of knockouts of EGFR ligands, which are milder than the phenotype of the EGFR knockout.
16. Luetteke, N. C. et al. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev. 8, 399-413 (1994).
17. Tzahar, E. et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16, 5276-5287 (1996).
18. Jones, R. B., Gordus, A., Krall, J. A. & Macbeath, G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Natures 439, 168-174 (2006).
19. Baulida, J., Kraus, M. H., Alimandi, M., Di Fiore, P. P. & Carpenter, G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271, 5251-5257 (1996).
20. Worthylake, R., Opresko, L. K. & Wiley, H. S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem. 274, 8865-8874 (1999).
21. Lenferink, A. E. et al. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17, 3385-3397 (1998).
22. Pinkas-Kramarski, R. et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452-2467 (1996). Shows that ERBB2, rather than functioning as an autonomous, ligand-activated receptor, is a shared co-receptor that amplifies the signalling potential of the other ERBBs.
23. Waterman, H., Alroy, I., Strano, S., Seger, R. & Yarden, Y. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J. 18, 3348-3358 (1999).
24. Wallasch, C. et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14, 4267-4275 (1995).
25. Srinivisan, R., Poulsom, R., Hurst, H. C. & Gullick, W. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J. Pathol. 185, 236-245 (1998).
26. Rio, C., Buxbaum, J. D., Peschon, J. J. & Corfas, G. Tumor necrosis factor-α-converting enzyme is required for cleavage of erbB4/HER4. J. Biol. Chem. 275, 10379-10387 (2000).
27. Elenius, K. et al. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 18, 2607-2615 (1999).
28. Ni, C. Y., Murphy, M. P., Golde, T. E. & Carpenter, G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294, 2179-2181 (2001). Description of ERBB4 cleavage that leads to formation of a soluble intracellular domain, which might function independently of the membrane-associated receptor.
29. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386-390 (1995).
30. Lee, K. F. et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378, 394-398 (1995).
31. Gassmann, M. et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390-394 (1995).
32. Riethmacher, D. et al. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature 389, 725-730 (1997).
33. Burgess, A. W. et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12, 541-552 (2003).
34. Gadella, T. W. & Jovin, T. M. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J. Cell Biol. 129, 1543-1558 (1995).
35. Lemmon, M. A. et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 16, 281-294 (1997).
36. Sako, Y., Minoghchi, S. & Yanagida, T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nature Cell Biol. 2, 168-172 (2000).
37. Moriki, T., Maruyama, H. & Maruyama, I. N. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J. Mol. Biol. 311, 1011-1026 (2001).
38. Clayton, A. H. et al. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A- multidimensional microscopy analysis. J. Biol. Chem. 280, 30392-30399 (2005).
39. Garrett, T. P. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110, 763-773 (2002).
40. Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 (2002). References 39 and 40 describe the structures of the ligand-bound extracellular domain of the EGFR and reveal the basis of ligand-induced receptor activation.
41. Garrett, T. P. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495-505 (2003).
42. Blagoev, B., Ong, S. E., Kratchmarova, I. & Mann, M. Temporal analysis of phosphotyroisne-dependent signaling networks by quantitative proteomics. Nature Biotechnol. 22, 1139-1145 (2004). Demonstration of the power of new high-throughput techniques for accumulation of quantitative information regarding signalling events.
43. Zhang, Y. et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell. Proteomics 4, 1240-1250 (2005).
44. Ma, H. W. & Zeng, A. P. The connectivity structure, giant strong component and centrality of metabolic networks. Bioinformatics 19, 1423-1430 (2003).
45. Kirschner, M. & Gerhart, J. Evolvability. Proc. Natl Acad. Sci. USA 95, 8420-8427 (1998).
46. Agrawal, A. A. Phenotypic plasticity in the interactions and evolution of species. Science 294, 321-326 (2001).
47. Okutani, T. et al. Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells. J. Biol. Chem. 269, 31310-31314 (1994).
48. Batzer, A. G., Rotin, D., Urena, J. M., Skolnik, E. Y. & Schlessinger, J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 14, 5192-5201 (1994).
49. Waterman, H. et al. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 21, 303-313 (2002).
50. Jiang, X., Huang, F., Marusyk, A. & Sorkin, A. Grb2 Regulates Internalization of EGF receptors through clathrin-coated pits. Mol. Biol. Cell. 14, 858-870 (2003).
51. Freeman, M. Feedback control of intercellular signalling in development. Nature 408, 313-319 (2000).
52. Schulze, A., Lehmann, K., Jefferies, H. B., McMahon, M. & Downward, J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15, 981-994 (2001).
53. Schafer, B., Gschwind, A. & Ullrich, A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23, 991-999 (2004).
54. Wiley, H. S. Trafficking of the ErbB receptors and its influence on signaling. Exp. Cell Res. 284, 78-88 (2003).
55. Berset, T. A., Hoier, E. F. & Hajnal, A. The C. elegans homolog of the mammalian tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate binary cell fate decisions. Genes Dev. 19, 1328-1340 (2005).
56. Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G. & Bastiaens, P. I. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295, 1708-1711 (2002).
57. Kario, E. et al. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J. Biol. Chem. 280, 7038-7048 (2005).
58. Hanafusa, H., Torii, S., Yasunaga, T. & Nishida, E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signaling pathway. Nature Cell Biol. 4, 850-858 (2002).
59. Reich, A., Sapir, A. & Shilo, B. Sprouty is a general inhibitor of receptor tyrosine kinase signaling. Development 126, 4139-4147 (1999).
60. Yusoff, P. et al. Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J. Biol. Chem. 277, 3195-3201 (2002).
61. Rubin, C. et al. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr. Biol. 13, 297-307 (2003).
62. Laederich, M. B. et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J. Biol. Chem. 279, 47050-47056 (2004).
63. Gur, G. et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 23, 3270-3281 (2004).
64. Hackel, P. O., Gishizky, M. & Ullrich, A. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol. Chem. 382, 1649-1662 (2001).
65. Fiorini, M. et al. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 21, 6530-6539 (2002).
66. Anastasi, S. et al. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22, 4221-4234 (2003).
67. Rutherford, S. L. & Lindquist, S. Hsp90 as a capacitor for morphological evolution. Nature 396, 336-342 (1998).
68. Neckers, L. & Ivy, S. P. Heat shock protein 90. Curr. Opin. Oncol. 15, 419-424 (2003).
69. Citri, A., Kochupurakkal, B. S. & Yarden, Y. The Achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3, 51-60 (2003).
70. c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271, 22796-22801 (1996). Early evidence which shows that HSP90 is a regulator of the ERBB network by modulating the stability of ERBB2.
71. Citri, A. et al. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep. 5, 1165-1170 (2004).
72. Tikhomirov, O. & Carpenter, G. Identification of ErbB2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res. 63, 39-43 (2003).
73. Xu, W. et al. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nature Struct Mol. Biol. 12, 120-126 (2005).
74. Wang, Q., Villeneuve, G. & Wang, Z. Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep. 6, 942-948 (2005).
75. Opresko, L. K. et al. Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of the tyrosine kinase domain. J. Biol. Chem. 270, 4325-4333 (1995).
76. Honegger, A., M. et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51, 199-209 (1987).
77. Herbst, J. J., Opresko, L. K., Walsh, B. J., Lauffenburger, D. A. & Wiley, H. S. Regulation of postendocytic trafficking of the epidermal growth factor receptor through endosomal retention. J. Biol. Chem. 269, 12865-12873 (1994).
78. Marmor, M. D. & Yarden, Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23, 2057-2070 (2004).
79. Wang, Z. & Moran, M. F. Requirement for the adapter protein GRB2 in EGF receptor endocytosis. Science 272, 1935-1938 (1996).
80. Petrelli, A. et al. The endophilin-CIN85-Cbl complex mediates ligand-dependent down regulation of c-Met. Nature 416, 187-190 (2002).
81. Soubeyran, P., Kowanetz, K., Szymkiewicz, I., Langdon, W. Y. & Dikic, I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 416, 183-187 (2002).
82. Katz, M. et al. Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic 3, 740-751 (2002).
83. Polo, S. et al. A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins. Nature 416, 451-455 (2002).
84. Amit, I. et al. Tal, a Tsg 101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev. 18, 1737-1752 (2004).
85. Katzmann, D. J., Odorizzi, G. & Emr, S. D. Receptor downregulation and multivesicular-body sorting. Nature Rev. Mol. Cell. Biol. 3, 893-905 (2002).
86. Di Guglielmo, G. M., Baass, P. C., Ou, W. J., Posner, B. I. & Bergeron, J. J. Compartmentalization of SHC, GRB2 and mSOS, and hyperphosphorylation of Raf-1 by EGF but not insulin in liver parenchyma. EMBO J. 13, 4269-4277 (1994).
87. Wang, Y., Pennock, S., Chen, X. & Wang, Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol. Cell. Biol. 22, 7279-7290 (2002).
88. Miaczynska, M. et al. APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. Cell 116, 445-456 (2004).
89. Vecchi, M., Baulida, J. & Carpenter, G. Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J. Biol. Chem. 271, 18989-18995 (1996).
90. Williams, C. C. et al. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J. Cell. Biol. 167, 469-478 (2004).
91. Komuro, A., Nagai, M., Navin, N. E. & Sudol, M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J. Biol. Chem. 278, 33334-33341 (2003).
92. Omerovic, J. et al. Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp. Cell Res. 294, 469-479 (2004).
93. Aqeilan, R. I. et al. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 65, 6764-6772 (2005).
94. Wang, S. C. et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6, 251-261 (2004).
95. Lo, H. W. et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7, 575-589 (2005).
96. Kholodenko, B. N. Cell signalling dynamics in time and space. Nature Rev. Mol. Cell. Biol. 7, 165-176 (2006).
97. Orton, R. J. et al. Computational modelling of the receptor-tyrosine- kinase-activated MAPK pathway. Biochem. J. 392, 249-261 (2005).
98. Wiley, H. S. & Cunningham, D. D. A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands. Cell 25, 433-440 (1981).
99. Starbuck, C. & Lauffenburger, D. A. Mathematical model for the effects of epidermal growth factor receptor trafficking dynamics on fibroblast proliferation responses. Biotechnol. Prog. 8, 132-143 (1992).
100. Wiley, H. S. et al. The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 266, 11083-11094 (1991).
101. Kholodenko, B. N., Demin, O. V., Moehren, G. & Hoek, J. B. Quantification of short term signaling by the epidermal growth factor receptor. J. Biol. Chem. 274, 30169-30181 (1999).
102. Schoeberl, B., Eichler-Jonsson, C., Gilles, E. D. & Muller, G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nature Biotechnol. 20, 370-375 (2002). References 101 and 102 describe the first attempts to formulate models of the early events following activation of the EGFR. These two models function as platforms for developing more complex models of EGFR signalling.
103. Resat, H., Ewald, J. A., Dixon, D. A. & Wiley, H. S. An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophys. J. 85, 730-743 (2003).
104. Maly, I. V., Wiley, H. S. & Lauffenburger, D. A. Self-organization of polarized cell signaling via autocrine circuits: computational model analysis. Biophys. J. 86, 10-22 (2004).
105. Oda, K., Matsuoka, Y., Funahashi, A. & Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1, 8-24 (2005).
106. Reddy, C. C., Niyogi, S. K., Wells, A., Wiley, H. S. & Lauffenburger, D. A. Engineering epidermal growth factor for enhanced mitogenic potency. Nature Biotech. 14, 1696-1699 (1996).
107. Tzahar, E. et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17, 5948-5963 (1998).
108. Haugh, J. M. & Lauffenburger, D. A. Analysis of receptor internalization as a mechanism for modulating signal transduction. J. Theoret. Biol. 195, 187-218 (1998).
109. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
110. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
111. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004). References 109-111 describe identification of activating mutations within the kinase domain of the EGFR. Patients whose tumours bear these mutations respond better to treatment with EGFR-specific kinase inhibitors.
112. Tracy, S. et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64, 7241-7244 (2004).
113. Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
114. Engelman, J. A. et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 102, 3788-3793 (2005).
115. Shigematsu, H. et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65, 1642-1646 (2005).
116. Ekstrand, A. J., Sugawa, N., James, C. D. & Collins, V. P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl Acad. Sci. USA 89, 4309-4313 (1992).
117. Ekstrand, A. J. et al. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 51, 2164-2172 (1991).
118. Liu, L. et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J. Mol. Med. 83, 917-926 (2005).
119. Huang, H. S. et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Biol. Chem. 272, 2927-2935 (1997).
120. Nicholson, R. I., Gee, J. M. & Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl. 4), S9-S15 (2001).
121. Ford, A. C. & Grandis, J. R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25, 67-73 (2003).
122. Ross, J. S. et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8, 307-325 (2003).
123. Slamon, D. J. et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244, 707-712 (1989). The first study to show that ERBB2 amplification predicts poor prognosis for breast cancer patients.
124. Hirai, T. et al. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biological markers. Dis. Esophagus 11, 221-225 (1998).
125. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S. & Sugimachi, K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 12, 1183-1188 (1990).
126. Hansen, M. R., Roehm, P. C., Chatterjee, P. & Green, S. H. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia 53, 593-600 (2006).
127. Moghal, N. & Sternberg, P. W. The epidermal growth factor system in Caenorhabditis elegans. Exp. Cell Res. 284, 150-159 (2003).
128. Shilo, B. Z. Signaling by the Drosophila epidermal growth factor receptor pathway during development. Exp. Cell Res. 284, 140-149 (2003).
129. Stein, R. A. & Staros, J. V. Evolutionary analysis of the ErbB receptor and ligand families. J. Mol. Evol. 50, 397-412 (2000).
130. Bray, D. & Lay, S. Computer simulated evolution of a network of cell-signaling molecules. Biophys. J. 66, 972-977 (1994).
131. Kitano, H. Cancer robustness: tumour tactics. Nature 426, 125 (2003).
132. Carlson, J. M. & Doyle, J. Highly optimized tolerance: robustness and design in complex systems. Phys. Rev. Lett. 84, 2529-2532 (2000).
133. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
134. Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004).
135. Spiridon, C. I. et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8, 1720-1730 (2002).
136. Friedman, L. M. et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl Acad. Sci. USA 102, 1915-1920 (2005).
137. Xia, W. et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21, 6255-6263 (2002).
138. Citri, A. et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21, 2407-2417 (2002).
139. Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727-1733 (1979).
140. Ye, D., Mendelsohn, J. & Fan, Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18, 731-738 1999).
141. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
142. Shou, J. et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96, 926-935 (2004).